Abstract: The present invention is related to the composition and methods of manufacture of orally-dissolvable, edible films as a vehicle for the non-invasive administration of nitroglycerin, as well as other therapeutic agents either with or without nitroglycerin, through the mucosal tissues of the oral cavity. The films include a water soluble film-forming polymer such as pullulan. Methods for producing the films are also disclosed.
Abstract: This document provides methods and materials for treating cardiovascular tissue. For example, stem cells, compositions containing stem cells, methods for obtaining stem cells, compositions for generating stem cells expressing particular markers (e.g., compositions comprising TGF-?1, BMP-2, FGF-4, and leukemia inhibitory factor), and methods for repairing cardiovascular tissue are provided.
Type:
Grant
Filed:
July 29, 2005
Date of Patent:
May 8, 2012
Assignee:
Mayo Foundation for Medical Education and Research
Abstract: A process of treating trauma induced factor V consumptive coagulopathy is presented whereby a subject is administered a preparation of isolated factor V or a variant thereof. Administration of factor V surprisingly improves clot times and reduces the severity and propensity of bleeding events.
Abstract: The present invention stems from the finding that the extracellular domain of CD31 proteins present on blood leukocytes is shed and released in the circulation as a soluble form of CD31. The invention relates to peptides corresponding to fragments of CD31 that inhibit T-cell response, and to their use in the treatment of thrombotic disorders such as atherothrombosis and autoimmune disorders.
Abstract: Provided are degradation-resistant fibrinogen sealants comprising a first composition comprising one or more of fibrinogen ?A/?? heterodimers and/or fibrinogen ??/?? homodimers and a second composition comprising thrombin and, optionally, degradation-resistant fibrinogen sealants disclosed herein may further comprise Factor XIII and calcium. Degradation-resistant fibrinogen sealants are suitable for the treatment of trauma, particularly vascular trauma.
Abstract: The present invention is directed to the following: methods of treating or preventing stent thrombosis using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; methods of reducing mortality in a subject undergoing stent implantation using pharmaceutical compositions comprising cangrelor and optionally bivalirudin; medicaments comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation; pharmaceutical compositions comprising cangrelor and bivalirudin; and methods of preparing a medicament comprising cangrelor and optionally bivalirudin useful for treating or preventing stent thrombosis, or useful for reducing mortality in a subject undergoing stent implantation.
Type:
Application
Filed:
November 10, 2010
Publication date:
May 12, 2011
Applicant:
THE MEDICINES COMPANY
Inventors:
Clive Arthur ARCULUS-MEANWELL, Simona SKERJANEC
Abstract: Disclosed are antibodies and antigen-binding fragments that bind to a complementary peptide having an amino acid sequence that is encoded by the complement of a nucleotide sequence encoding thrombin or a portion thereof. Such antibodies and antigen-binding fragments can be agonists or antagonists of thrombin receptor-mediated events. Also disclosed are methods of using the agonist antibodies and antigen-binding fragments of the invention to activate the non-proteolytically activated thrombin receptor (NPAR) in a subject in need of such treatment. In addition, methods of using the antagonist antibodies and antigen-binding fragments of the invention to inhibit activation of the NPAR in a subject in need of such treatment are disclosed.
Type:
Grant
Filed:
September 14, 2006
Date of Patent:
May 3, 2011
Assignee:
Orthologic Corp.
Inventors:
Darrell H. Carney, John S. Bergmann, Gerald M. Fuller
Abstract: ATIII is a serine proteinase inhibitor (serpin) with anti-coagulant, anti-inflammatory, anti-proliferative and anti-angiogenic properties. The invention features methods of treating a subject having lung injury due to burns and smoke inhalation by administering a synergistic combination of antithrombin III and heparin through pulmonary delivery means.
Type:
Application
Filed:
September 10, 2010
Publication date:
March 24, 2011
Inventors:
Perenlei Enkhbaatar, Kazunori Murakami, Daniel L. Traber
Abstract: The present invention is directed to a hemostatic composite structure having a bioabsorbable fabric or non-woven substrate having at least two major oppositely facing surface areas and a continuous non-porous polymer-based film that is laminated on one major surface of said substrate. The bioabsorbable fabric substrate can be an oxidized polysaccharide and/or the non-woven substrate can be made from bioabsorbable, non-cellulosic derived polymers. The continuous non-porous polymer based film can be a bioabsorbable polymer. The present invention also relates to a method for providing hemostasis by applying a composite structure described herein onto a wound site in need of a hemostatic device wherein a major surface of the substrate without the film layer is applied onto the wound site.
Abstract: The present invention relates to a chromogenic test reagent which comprises a chromogenic peptide substrate and an inhibitor of fibrin polymerization, which is particularly suitable for being used in coagulation-diagnostic tests and which is distinguished by the fact that it exhibits a nigh degree of stability and/or a long shelf life in the liquid state.
Abstract: The present invention relates to a polypeptide exhibiting a protease inhibitory activity and uses of said polypeptide in methods for inhibiting, directly or indirectly, one or more proteases of the blood clotting cascade. The invention also relates to use of said polypeptide as a pharmaceutical e.g. for prophylactic or ameliorating treatment of blood clots. In addition the invention comprises methods for production of said polypeptide.